148 related articles for article (PubMed ID: 16778826)
21. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
22. C-kit and PDGFRA gene mutations in triple negative breast cancer.
Zhu Y; Wang Y; Guan B; Rao Q; Wang J; Ma H; Zhang Z; Zhou X
Int J Clin Exp Pathol; 2014; 7(7):4280-5. PubMed ID: 25120810
[TBL] [Abstract][Full Text] [Related]
23. Site-dependent differential KIT and PDGFRA expression in gastric and intestinal gastrointestinal stromal tumors.
Haller F; Happel N; Schulten HJ; von Heydebreck A; Schwager S; Armbrust T; Langer C; Gunawan B; Doenecke D; Füzesi L
Mod Pathol; 2007 Oct; 20(10):1103-11. PubMed ID: 17673922
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
25. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
26. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
28. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: Correlation with tumor site, tumor size, exon, and CD117 immunohistochemistry.
Wallander ML; Willmore-Payne C; Layfield LJ
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):21-7. PubMed ID: 20823768
[TBL] [Abstract][Full Text] [Related]
29. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
[TBL] [Abstract][Full Text] [Related]
30. KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential.
Kontogianni-Katsarou K; Dimitriadis E; Lariou C; Kairi-Vassilatou E; Pandis N; Kondi-Paphiti A
World J Gastroenterol; 2008 Mar; 14(12):1891-7. PubMed ID: 18350628
[TBL] [Abstract][Full Text] [Related]
31. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.
Wasag B; Debiec-Rychter M; Pauwels P; Stul M; Vranckx H; Oosterom AV; Hagemeijer A; Sciot R
Mod Pathol; 2004 Aug; 17(8):889-94. PubMed ID: 15154005
[TBL] [Abstract][Full Text] [Related]
33. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Medeiros F; Corless CL; Duensing A; Hornick JL; Oliveira AM; Heinrich MC; Fletcher JA; Fletcher CD
Am J Surg Pathol; 2004 Jul; 28(7):889-94. PubMed ID: 15223958
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
Lassus H; Sihto H; Leminen A; Nordling S; Joensuu H; Nupponen NN; Butzow R
Br J Cancer; 2004 Dec; 91(12):2048-55. PubMed ID: 15583695
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status.
Jaramillo S; Ríos-Moreno MJ; Hernández A; Amérigo J; Trigo-Sánchez I; González-Cámpora R
Rev Esp Enferm Dig; 2012 Mar; 104(3):128-33. PubMed ID: 22449154
[TBL] [Abstract][Full Text] [Related]
36. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
[TBL] [Abstract][Full Text] [Related]
37. Epithelioid gastrointestinal stromal tumor with PDGFRA activating mutation and immunoreactivity.
Yi ES; Strong CR; Piao Z; Perucho M; Weidner N
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):157-61. PubMed ID: 15894928
[TBL] [Abstract][Full Text] [Related]
38. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.
Rege TA; Wagner AJ; Corless CL; Heinrich MC; Hornick JL
Am J Surg Pathol; 2011 Apr; 35(4):495-504. PubMed ID: 21358303
[TBL] [Abstract][Full Text] [Related]
39. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?
Carvalho S; e Silva AO; Milanezi F; Ricardo S; Leitão D; Amendoeira I; Schmitt FC
J Clin Pathol; 2004 Oct; 57(10):1075-9. PubMed ID: 15452163
[TBL] [Abstract][Full Text] [Related]
40. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
